Fast Five Quiz: Secondary Prevention of Cardiovascular Disease

Yasmine S. Ali, MD


December 14, 2020

BP control is important for the secondary prevention of CVD. According to guidelines from the American Heart Association (AHA) and the American College of Cardiology Foundation, BP medication should be prescribed for patients with BP ≥ 140/90 mm Hg, as tolerated. Initial treatment with beta-blockers and/or angiotensin-converting enzyme (ACE) inhibitors is recommended, with the addition of other drugs as needed to achieve BP goal. Among patients with diabetes or chronic kidney disease, BP medication should be initiated when BP is ≥ 130/80 mm Hg.

Prescription-strength omega-3 fatty acids are indicated for the treatment of hypertriglyceridemia, not hypertension. A recent AHA Science Advisory recommended prescription-strength omega-3 fatty acids (4 g/d) as monotherapy or as an adjunct to other lipid-lowering agents.

Learn more about secondary prevention of CVD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.